title: A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
abstract: As part of a drug discovery program to discover more effective platinum-based anticancer drugs, a series of platinum complexes of trans coordination geometry centered on trans-ammine(cyclohexylaminedichlorodihydroxo)platinum(IV) (JM335) has been evaluated in vitro against a panel of cisplatin-sensitive and cisplatin-resistant human tumor cell lines (predominantly ovarian). In vitro, against 5 human ovarian carcinoma cell lines, JM335 was comparably cytotoxic to cisplatin itself and over 50-fold more potent than transplatin (mean 50% inhibitory concentrations: JM335, 3.1 microM; cisplatin, 4.1 microM; transplatin, 162 microM). With the use of seven pairs of human tumor cell lines (parent and subline with acquired resistance to cisplatin and encompassing all of the known major mechanisms of resistance to cisplatin) JM335 exhibited a different cross-resistance pattern to that of its cis isomer (JM149). JM335 showed non-cross-resistance in six of the seven resistant lines, cross-resistance in the A2780cisR line possibly being associated with high levels of glutathione. Preliminary intracellular DNA binding studies showed that in contrast to transplatin, JM335 was efficient at forming DNA-DNA interstrand cross-links. In vivo, JM335 produced growth delays in excess of 15 days against 4 of 6 human ovarian carcinoma xenografts and was unique among the complexes studied in retaining some efficacy against a cisplatin-resistant subline of the murine ADJ/PC6 plasmacytoma. JM335 is the first trans-platinum complex to demonstrate marked antitumor efficacy against both murine and human s.c. tumor models and represents a significant structural lead to complexes capable of circumventing cross-resistance to cisplatin.
authors.affiliation: CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Belmont, Sutton, Surrey, United Kingdom.
authors.forename: L R
authors.initials: LR
authors.lastname: Kelland
authors.forename: C F
authors.initials: CF
authors.lastname: Barnard
authors.forename: K J
authors.initials: KJ
authors.lastname: Mellish
authors.forename: M
authors.initials: M
authors.lastname: Jones
authors.forename: P M
authors.initials: PM
authors.lastname: Goddard
authors.forename: M
authors.initials: M
authors.lastname: Valenti
authors.forename: A
authors.initials: A
authors.lastname: Bryant
authors.forename: B A
authors.initials: BA
authors.lastname: Murrer
authors.forename: K R
authors.initials: KR
authors.lastname: Harrap
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D002945:Cisplatin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D004273:DNA, Neoplasm / Q000378:metabolism; D004351:Drug Resistance; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D051379:Mice; D009944:Organoplatinum Compounds / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D009944:Organoplatinum Compounds; C034697:transplatin; D002945:Cisplatin; C043804:diamminedichlorodihydroxyplatinum IV